Inactive Instrument

Press Releases BioAlliance Pharma SA Euronext Paris

Equities

C4X

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-

2023	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Onxeo SA has Changed its Name to Valerio Therapeutics	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	23-06-06	PU
Onxeo: Publication of the 2022 Annual Financial Report	23-04-28	BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	23-04-24	BU
Onxeo will publish its full-year results on April 24, 2023	23-04-21	BU
Onxeo : Terms of availability of the preparatory documents for the GM	23-01-18	PU
Half-year liquidity contract statement for ONXEO	23-01-04	BU
Onxeo : Inside Information / News release on accounts, results	22-09-13	PU
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	22-09-13	BU
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	22-09-01	BU
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen	22-08-30	BU
Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen	22-08-17	BU
Onxeo S.A.: Combined General Meeting of August 17, 2022: Availability of Preparatory Documents and Participation & Voting Procedures	22-07-29	BU
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures	22-07-29	PU
Onxeo : Inside Information / Other news releases	22-07-12	PU
Onxeo Announces a Combined General Meeting on August 17, 2022	22-07-12	BU
Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux	22-07-04	BU
Onxeo: Initial IND Application for AsiDNA Granted “Study May Proceed” by the U.S. FDA	22-06-30	BU
Onxeo : Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA	22-06-30	PU
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022	22-06-16	BU
Onxeo: Publication of the 2021 Annual Financial Report	22-04-28	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioAlliance Pharma SA Euronext Paris

Equities

C4X

Press Releases

Filters